APGE — Apogee Therapeutics, Inc. Common Stock

Apogee Therapeutics, Inc. Common Stock (APGE) is a biotechnology company listed on NASDAQ. It is led by Michael Thomas Henderson M.D., based in Building 17, Waltham, MA, United States, 02453, with about 196 employees. Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Net income was -$186.5M. APGE currently screens at market cap $2.34B.

Use this APGE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the APGE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the APGE SEC filings page. Lician reads the product cache first so this HTML stays unique to Apogee Therapeutics, Inc. Common Stock even when a live quote feed is slow.